(EN-zuh-LOO-tuh-mide)
This page contains brief information about enzalutamide and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Enzalutamide is approved to treat:
- Prostate cancer. It is used:
- In patients whose cancer is castrate resistant (has not responded to treatments that lower testosterone levels).
- In patients whose cancer has spread to other parts of the body and is castrate sensitive (has responded to treatments that lower testosterone levels).
- In patients whose cancer has not spread to other parts of the body, is castrate sensitive, and is in biochemical recurrence and at high risk of spreading to other parts of the body.
Enzalutamide is also being studied in the treatment of other types of cancer.
More About Enzalutamide
Definition from the NCI Drug Dictionary – Detailed scientific definition and other names for this drug.
More About Enzalutamide – A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Enzalutamide Gets Added Approval for Prostate Cancer That Hasn’t Spread
FDA Approves New Initial Treatment Option for Some Metastatic Prostate Cancers
Hormone Therapy for Prostate Cancer
Clinical Trials Accepting Patients
Find Clinical Trials for Enzalutamide – Check for trials from NCI’s list of cancer clinical trials now accepting patients.